Yu Hua Quan1, Byungji Kim2, Ji-Ho Park2, Yeonho Choi1,3,Young Ho Choi1, Hyun Koo Kim1
1Department of Thoracic and Cardiovascular Surgery, Korea University College of Medicine, Seoul, 152-703, Korea
In spite of severe side effects, chemotherapy is widely used as a major anticancer treatment in non-small cell lung cancer (NSCLC). HA polymers have become a topic of interest for developing sustained drug delivery systems of peptide and protein drugs in subcutaneous formulations. Based on our experimental results, we strongly believe that HA-cisplatin conjugate is a potential anti-cancer chemo-agent, which target CD44 overexpression in NSCLC, with minimal side effects and high therapeutic properties.